Waljee AK, Higgins PDR, Jensen CB, et al. - In patients (≥ 18 years) with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer, researchers conducted this Danish, population-based cohort study to evaluate the risk of recurrence of initial cancer or development of a new primary cancer after treatment with anti-tumour necrosis factor-α (TNFα) therapy. Overall, 25,738 individuals with immune-mediated disease and a history of cancer have been identified. Four hundred thirty-four patients who received anti-TNFα therapy after their initial cancer were matched to 4,328 patients in the control group. Data reported that the median time between anti-TNFα treatment and recurrent or new primary cancer diagnosis was 2·8 years. In patients with previous cancer, anti-TNFα therapy use was not linked to recurrent or new primary cancer development. Timing of anti-TNFα therapy following an initial cancer diagnosis did not affect recurrent or new primary cancer development. This observation could guide clinical decision-making among providers that use anti-TNFα drugs to treat immune-mediated diseases.